Praxis Precision Medicines Inc Dossier
Qualitative Analysis
Business overview
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on translating genetic insights into the development of precision therapies for central nervous system (CNS) disorders. The company's pipeline is built on two proprietary platforms: Cerebrum™, which focuses on small molecule therapies, and Solidus™, which utilizes antisense oligonucleotide (ASO) technologies. Praxis targets neurological conditions characterized by neuronal excitation-inhibition (E/I) imbalance, with a primary focus on movement disorders (such as essential tremor) and rare genetic epilepsies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial roadmap and patient identification to prepare for the potential U.S. launches of relutrigine and ulixacaltamide following FDA acceptance of their NDAs.
Expected impact: Successful market entry and commercialization of lead CNS assets.
Advancing three early-stage antisense oligonucleotide (ASO) therapeutic initiatives: PRAX-080 (PCDH19), PRAX-090 (SYNGAP1), and PRAX-100 (SCN2A LoF) to nominate development candidates.
Expected impact: Broadening the precision neuroscience pipeline with novel genetic epilepsy candidates.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborative research and global development of small molecule therapeutics targeting KCNT1-related epilepsies, validating Praxis' proprietary platforms.
Terms: Praxis received an upfront payment and earned an option exercise fee in December 2024. Eligible for up to $100 million in total success-based milestones plus tiered royalties.
Joint development of elsunersen (investigational ASO treatment for SCN2A-DEE) currently in the EMBRAVE3 clinical study.
Terms: Collaborative development terms with shared clinical execution.